By:  Dominguez, et al. H.B. No. 1802

     (Senate Sponsor - Campbell, et al.)

(In the Senate - Received from the House May 10, 2021; May 17, 2021, read first time and referred to Committee on Veteran Affairs & Border Security; May 19, 2021, reported favorably by the following vote: Yeas 6, Nays 0; May 19, 2021, sent to printer.)

COMMITTEE VOTE

               Yea Nay Absent  PNV

Campbell        X

Hall            X

Blanco          X

Eckhardt        X

Gutierrez       X

Seliger                   X

Taylor          X

A BILL TO BE ENTITLED

AN ACT

relating to a study on the use of alternative therapies for treating post-traumatic stress disorder.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1.  (a) In this Act, "commission" means the Health and Human Services Commission.

(b)  The commission, in collaboration with Baylor College of Medicine and in partnership with a military veterans hospital or a medical center that provides medical care to veterans, shall conduct a study on the efficacy of using alternative therapies, including the use of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine, in the treatment of veterans who suffer from post-traumatic stress disorder.

(c)  In conducting the study described by Subsection (b) of this section, the commission in collaboration with the Baylor College of Medicine shall:

(1)  perform a clinical trial on the therapeutic efficacy of using psilocybin in the treatment of treatment-resistant post-traumatic stress disorder in veterans; and

(2)  review current literature regarding:

(A)  the safety and efficacy of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine in the treatment of post-traumatic stress disorder; and

(B)  the access veterans have to 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine for treatment of post-traumatic stress disorder in the United States.

(d)  The commission shall prepare and submit to the governor, the lieutenant governor, the speaker of the house of representatives, and each member of the legislature:

(1)  quarterly reports on the progress of the study conducted under this section; and

(2)  not later than December 1, 2024, a written report containing the results of the study conducted under this section and any recommendations for legislative or other action.

(e)  The commission shall ensure any protected health information collected during a clinical trial conducted under Subsection (c) of this section and reported under Subsection (d) of this section does not personally identify an individual.

(f)  This Act expires September 1, 2025.

SECTION 2.  This Act takes effect immediately if it receives a vote of two-thirds of all the members elected to each house, as provided by Section 39, Article III, Texas Constitution. If this Act does not receive the vote necessary for immediate effect, this Act takes effect September 1, 2021.

\* \* \* \* \*